ICAD, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
March 12, 2024 at 04:05 pm EDT
Share
iCAD, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 4.74 million compared to USD 4.64 million a year ago. Net income was USD 1.36 million compared to net loss of USD 3.1 million a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.09 a year ago. Diluted loss per share from continuing operations was USD 0.02 compared to USD 0.09 a year ago. Basic earnings per share was USD 0.05 compared to basic loss per share of USD 0.12 a year ago. Diluted earnings per share was USD 0.05 compared to diluted loss per share of USD 0.12 a year ago.
For the full year, revenue was USD 17.32 million compared to USD 19.8 million a year ago. Net loss was USD 4.85 million compared to USD 13.66 million a year ago. Basic loss per share from continuing operations was USD 0.27 compared to USD 0.39 a year ago. Diluted loss per share from continuing operations was USD 0.27 compared to USD 0.39 a year ago. Basic loss per share was USD 0.19 compared to USD 0.54 a year ago. Diluted loss per share was USD 0.19 compared to USD 0.54 a year ago.
iCAD, Inc. is a global medical technology company, which provides cancer detection and therapy solutions. The Company is focused on providing breast cancer detection solutions built on artificial intelligence (AI) that empowers radiologists to find cancers. Its solutions include advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the most prevalent cancers earlier, and a range of high-performance, AI and computer-aided detection (CAD) systems and workflow solutions for 2D and 3D mammography, magnetic resonance imaging and computed tomography (CT). The Companyâs Breast AI Suite offers a triple threat of clinically proven cancer detection, density assessment, and risk evaluation solutions, designed to accelerate discovery and improve outcomes. It also offers ProFound AI, a digital breast tomosynthesis (DBT) cancer detection and workflow solution.
ICAD, INC. 
